Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease

NCT06254482 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06254482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06254482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 25, 2023
Completion date
July 16, 2029
Enrollment
144 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

huntington disease